237 related articles for article (PubMed ID: 26709902)
21. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
Tiwari P; Khan H; Singh TG; Grewal AK
Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
[TBL] [Abstract][Full Text] [Related]
22. NAD+ as a metabolic link between DNA damage and cell death.
Ying W; Alano CC; Garnier P; Swanson RA
J Neurosci Res; 2005 Jan 1-15; 79(1-2):216-23. PubMed ID: 15562437
[TBL] [Abstract][Full Text] [Related]
23. NADP
Bian C; Zhang C; Luo T; Vyas A; Chen SH; Liu C; Kassab MA; Yang Y; Kong M; Yu X
Nat Commun; 2019 Feb; 10(1):693. PubMed ID: 30741937
[TBL] [Abstract][Full Text] [Related]
24. Detecting and Quantifying pADPr In Vivo.
Lamade AM; Chen Y; Johnson CJ; Bayır H; Clark RSB
Methods Mol Biol; 2023; 2609():23-42. PubMed ID: 36515827
[TBL] [Abstract][Full Text] [Related]
25. Modulation of transcription by PARP-1: consequences in carcinogenesis and inflammation.
Aguilar-Quesada R; Muñoz-Gámez JA; Martín-Oliva D; Peralta-Leal A; Quiles-Pérez R; Rodríguez-Vargas JM; Ruiz de Almodóvar M; Conde C; Ruiz-Extremera A; Oliver FJ
Curr Med Chem; 2007; 14(11):1179-87. PubMed ID: 17504138
[TBL] [Abstract][Full Text] [Related]
26. Poly (ADP-ribose) polymerase, nitric oxide and cell death.
Pieper AA; Verma A; Zhang J; Snyder SH
Trends Pharmacol Sci; 1999 Apr; 20(4):171-81. PubMed ID: 10322503
[TBL] [Abstract][Full Text] [Related]
27. Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Badawy AA
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33063092
[TBL] [Abstract][Full Text] [Related]
28. Poly(ADP-ribose) polymerase-1-induced NAD(+) depletion promotes nuclear factor-κB transcriptional activity by preventing p65 de-acetylation.
Kauppinen TM; Gan L; Swanson RA
Biochim Biophys Acta; 2013 Aug; 1833(8):1985-91. PubMed ID: 23597856
[TBL] [Abstract][Full Text] [Related]
29. Detection of poly(ADP-ribose) polymerase activation in oxidatively stressed cells and tissues using biotinylated NAD substrate.
Bakondi E; Bai P; Szabó E E; Hunyadi J; Gergely P; Szabó C; Virág L
J Histochem Cytochem; 2002 Jan; 50(1):91-8. PubMed ID: 11748298
[TBL] [Abstract][Full Text] [Related]
30. Pathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP).
Islam BU; Habib S; Ahmad P; Allarakha S; Moinuddin ; Ali A
Indian J Clin Biochem; 2015 Oct; 30(4):368-85. PubMed ID: 26788021
[TBL] [Abstract][Full Text] [Related]
31. Ischemic brain injury is mediated by the activation of poly(ADP-ribose)polymerase.
Endres M; Wang ZQ; Namura S; Waeber C; Moskowitz MA
J Cereb Blood Flow Metab; 1997 Nov; 17(11):1143-51. PubMed ID: 9390645
[TBL] [Abstract][Full Text] [Related]
32. Poly(ADP-ribose) polymerase inhibitors: new pharmacological functions and potential clinical implications.
de la Lastra CA; Villegas I; Sánchez-Fidalgo S
Curr Pharm Des; 2007; 13(9):933-62. PubMed ID: 17430191
[TBL] [Abstract][Full Text] [Related]
33. Poly(ADP-ribose) polymerase 1 inhibition prevents interleukin-1β-induced inflammation in human osteoarthritic chondrocytes.
Sun Y; Zhou L; Lv D; Liu H; He T; Wang X
Acta Biochim Biophys Sin (Shanghai); 2015 Jun; 47(6):422-30. PubMed ID: 25926140
[TBL] [Abstract][Full Text] [Related]
34. Cytoprotective effect of gallotannin in oxidatively stressed HaCaT keratinocytes: the role of poly(ADP-ribose) metabolism.
Bakondi E; Bai P; Erdélyi K; Szabó C; Gergely P; Virág L
Exp Dermatol; 2004 Mar; 13(3):170-8. PubMed ID: 14987257
[TBL] [Abstract][Full Text] [Related]
35. Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy.
Cepeda V; Fuertes MA; Castilla J; Alonso C; Quevedo C; Soto M; Pérez JM
Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):39-53. PubMed ID: 18221025
[TBL] [Abstract][Full Text] [Related]
36. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
37. PARP-1 inhibitor alleviates cerebral ischemia/reperfusion injury by reducing PARylation of HK-1 and LDH in mice.
Chen YL; Wang Y; Fang QY; Wang T; Chen C; Gao TY; Wu M; Zhang WP; Lu YB
Eur J Pharmacol; 2024 Mar; 967():176377. PubMed ID: 38346469
[TBL] [Abstract][Full Text] [Related]
38. Synthesis and Evaluation of a Mitochondria-Targeting Poly(ADP-ribose) Polymerase-1 Inhibitor.
Krainz T; Lamade AM; Du L; Maskrey TS; Calderon MJ; Watkins SC; Epperly MW; Greenberger JS; Bayır H; Wipf P; Clark RSB
ACS Chem Biol; 2018 Oct; 13(10):2868-2879. PubMed ID: 30184433
[TBL] [Abstract][Full Text] [Related]
39. The pathogenesis of diabetic complications: the role of DNA injury and poly(ADP-ribose) polymerase activation in peroxynitrite-mediated cytotoxicity.
Kiss L; Szabó C
Mem Inst Oswaldo Cruz; 2005 Mar; 100 Suppl 1():29-37. PubMed ID: 15962096
[TBL] [Abstract][Full Text] [Related]
40. Poly(ADP-ribose) polymerase: the nuclear target in signal transduction and its role in brain ischemia-reperfusion injury.
Strosznajder RP; Jesko H; Zambrzycka A
Mol Neurobiol; 2005; 31(1-3):149-67. PubMed ID: 15953818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
